Literature DB >> 12797387

Flucytosine and cryptococcosis: which in vitro test is the best predictor of outcome?

M A Viviani1, M C Esposto, M Cogliati, A M Tortorano.   

Abstract

The combination of flucytosine and amphotericin B is first choice treatment for active cryptococcosis. Because of innate or acquired resistance of Cryptococcus neoformans to flucytosine, in vitro testing is mandatory. Yeast nitrogen base (YNB) at pH 7.0 is the recommended medium for the broth microdilution test (NCCLS M27-A) and for the E-test. In order to verify if minimum inhibitory concentrations (MICs) were able to predict treatment outcome, the susceptibility of 24 isolates from 21 patients treated with flucytosine alone or in combination was tested by the broth microdilution, agar dilution and E-test using YNB either at pH 7.0 or at pH 5.4. Only those MICs obtained on YNB pH 5.4 proved to correlate with treatment outcome. The present study suggests that in vitro susceptibility to flucytosine of C. neoformans isolates should be evaluated on YNB pH 5.4 and the test should be standardized accordingly.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12797387     DOI: 10.1179/joc.2003.15.2.124

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  8 in total

1.  Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates.

Authors:  D T A Te Dorsthorst; J W Mouton; C J P van den Beukel; H A L van der Lee; J F G M Meis; P E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

2.  In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus.

Authors:  Paul E Verweij; Debbie T A Te Dorsthorst; Willem H P Janssen; Jacques F G M Meis; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2008-09-15       Impact factor: 5.191

3.  Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.

Authors:  E Dannaoui; M Abdul; M Arpin; A Michel-Nguyen; M A Piens; A Favel; O Lortholary; F Dromer
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

4.  Comparison of MIC Test Strip and Sensititre YeastOne with the CLSI and EUCAST Broth Microdilution Reference Methods for In Vitro Antifungal Susceptibility Testing of Cryptococcus neoformans.

Authors:  Fatima Zohra Delma; Abdullah M S Al-Hatmi; Jochem B Buil; Hein van der Lee; Marlou Tehupeiory-Kooreman; G Sybren de Hoog; Joseph Meletiadis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

5.  Relationship between in vitro activities of amphotericin B and flucytosine and pH for clinical yeast and mold isolates.

Authors:  D T A te Dorsthorst; P E Verweij; J F G M Meis; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 6.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

7.  Subcutaneous cryptococcosis due to Cryptococcus diffluens in a patient with sporotrichoid lesions case report, features of the case isolate and in vitro antifungal susceptibilities.

Authors:  A Serda Kantarcioğlu; Teun Boekhout; G Sybren De Hoog; Bart Theelen; Ayhan Yücel; Tuba R Ekmekci; Bettina C Fries; Reiko Ikeda; Adem Koslu; Kemal Altas
Journal:  Med Mycol       Date:  2007-03       Impact factor: 4.076

8.  Sterol-Response Pathways Mediate Alkaline Survival in Diverse Fungi.

Authors:  Hannah E Brown; Calla L Telzrow; Joseph W Saelens; Larissa Fernandes; J Andrew Alspaugh
Journal:  mBio       Date:  2020-06-16       Impact factor: 7.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.